Metastatic melanoma

Balch CM, Soong S-J, Shaw HM, et al.: An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In Cutaneous Melanoma edn 2. Edited by Balch CM, Houghton AN, Milton GW, et al. Philadelphia: JB Lippincott, 1992:165.

Barth A, Wanek LA, Morton D: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995, 181:193.

Ahmann DL, Creagan ET, Hahn RG, et al.: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989, 63:224–227.

Lee SM, Betticher DC, Thatcher N: Melanoma: chemotherapy. Br Med Bull 1995, 51:609–630.

Hill G II, Krementz E, Hill H: Dimethyl triazenol imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy. Central Oncology Grow Protocols 7130, 7131, and 7131A. Cancer 1984, 53:1299.

Legha SS, Ring S, Papadopoulsa N, et al.: A phase II trial of taxol in metastatic melanoma. Cancer 1990, 65:2478–2481.

Einzig AI, Hochster H, Wiernik PH, et al.: A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991, 9:59–64.

Einzig AI, Schuchter LM, Recio A, et al.: Phase II trial of docetaxel (taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med Oncol 1996, 13:111–117.

Bleehen NM, Newlands SM, Thatcher LN, et al.: Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995, 13:910–913.

Summers Y, Middleton MR, Calvert H, et al.: Effect of Temozolomide (TMZ) on central nervous system (CNS) relapse in patients with advanced melanoma. Proc Am Soc Clin Oncol 1999, 18:A2048.

Del Prete SA, Maurer LH, O’Donnell J, et al.: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984, 68:1403–1405. This is the first paper reporting the activity of the Dartmouth regimen.

Legha SS, Ring S, Papadopoulos N, et al.: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989, 64:2024.

McClay EF, Mastrangelo MJ, Berd D, et al.: Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992, 50:553–556.

Margolin KA, Liu P-Y, Flaherty LE, et al.: Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a southwest oncology group study. J Clin Oncol 1998, 16:664–669. Results of the large phase II study of the Dartmouth regimen.

Saxman SB, Meyers ML, Chapman PB, et al.: A phase III multicenter randomized trial of DTIC, cisplatin, BCNU and tamoxifen versus DTIC alone in patients with metastatic melanoma. J Clin Oncol 1999, 18:A2068. Very important paper that showed lack of benefit of the Dartmouth regimen in a randomized clinical study.

Buzaid AC, Legha S, Winn R, et al.: Cisplatin (C) vinblastine (V), and dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a phase III Cancer Community Oncology program (CCOP) trial [abstract]. Proc Am Soc Clin Oncol 1993, 12:389.

Argawala SS, Kirkwood JM: Interferons in melanoma. Curr Opin Oncol 1996, 8:167.

Atkins MB: The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 1997, 9:205.

Kirkwood JM, Strwderman MH, Ernstoff MS, et al.:Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996, 14:7–17.

Atkins MB, Lotze M, Dutcher JP, et al.: High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated from 1985–1993. J Clin Oncol 1999, 17:2105–2116. Updated analysis of IL-2 data that led to FDA approval for IL-2 in advanced melanoma.

Sparano JA, Fisher RI, Sunderland M, et al.: Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993, 11:1969.

Falkson CI, Ibrahim J, Kirkwood JM, et al.: Phase III trial of dacarbazine versus dacarbazine with interferon a-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon a-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998, 16:1743–1751.

Legha SS, Ring S, Eton O, et al.: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998, 16:1752–1759.

Stoter G, Aamdal S, Rodenhuis S, et al.: Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol 1991, 9:1687–1691.

Richards JM, Mehta N, Ramming K, et al.: Sequential chemotherapy/immunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992, 10:1388–1343.

Atkins MS, O’Boyle KR, Sosman JA, et al.: Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994, 12:1553.

Rosenberg SA, Yang JC, Schwartzentruber DJ, et al.:Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999, 17:968–975. One of the first randomized trials of biochemotherapy.

Ang K, Geara F, Byers R, Peters L: Radiotherapy for melanoma. In Cutaneous Melanoma edn 3. Edited by Balch CM. St. Louis: Quality Medical Publishing; 1998:389–403.

Karakousis CP, Velez A, Driscoll DL, et al.: Metastectomy in malignant melanoma. Surgery 1994, 115:295.